Financials in USD. Standardized financial statements.
A compact view of how Neurocrine Biosciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788.10M | $451.20M | $161.63M | $15.00M |
| Revenue Growth? | +21.4% | +24.8% | +26.8% | +31.3% | +8.4% | +32.7% | +74.7% | +179.2% | +977.5% | 0.0% |
| Cost of Revenue? | $52.10M | $34.00M | $39.70M | $23.20M | $14.30M | $10.10M | $7.40M | $4.90M | $1.25M | $0 |
| Gross Profit? | $2.81B | $2.32B | $1.85B | $1.47B | $1.12B | $1.04B | $780.70M | $446.30M | $160.37M | $15.00M |
| Gross Margin? | +98.2% | +98.6% | +97.9% | +98.4% | +98.7% | +99.0% | +99.1% | +98.9% | +99.2% | +100.0% |
| Operating Expenses? | $2.19B | $1.75B | $1.60B | $1.22B | $1.02B | $872.80M | $708.40M | $409.50M | $291.73M | $162.37M |
| Operating Income? | $619.10M | $570.50M | $250.90M | $249.00M | $102.50M | $163.00M | $72.30M | $36.80M | -$131.36M | -$147.37M |
| EBITDA? | $666.60M | $639.70M | $416.10M | $264.60M | $138.10M | $148.10M | $85.90M | $56.30M | -$120.62M | -$139.64M |
| Income Before Tax | $705.40M | $486.00M | $332.10M | $213.90M | $101.40M | $106.70M | $46.50M | $21.84M | -$142.54M | -$141.09M |
| Income Tax Expense | $226.80M | $144.70M | $82.40M | $59.40M | $11.80M | -$300.60M | $9.50M | $730,000 | $0 | $0 |
| Net Income? | $478.60M | $341.30M | $249.70M | $154.50M | $89.60M | $407.30M | $37.00M | $21.11M | -$142.54M | -$141.09M |
| EPS? | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 | $4.37 | $0.40 | $0.22 | $-1.62 | $-1.63 |
| Diluted EPS? | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality